LTR Pharma executed a definitive commercial agreement with U.S. telehealth company Shed Holdings LLC, establishing the commercial framework for the planned U.S. commercialisation of ROXUS and including a commitment to support delivery of not less than 150,000 units during the first 12 months following Commercial Launch. In this episode, James examines what the agreement covers, the commercial structure, key milestones ahead of launch, and what investors should watch next.